Leronlimab Talk - Dr. Nader Pourhassan CEO of CytoDyn
Find more lectures and answers to COVID-19 related questions on DrBeen.Com
DrBeen team and #koolbeens are super excited to have Dr. Pourhassan with us today. We will discuss Leronlimab with Dr. Pourhassan.
#koolbeens have asked a tons of questions to ask Dr. Pourhassan.
From CytoDyn’s site:
CytoDyn is committed to enhancing the lives of patients through target specific medicine. Our team is focused on developing Leronlimab, a monoclonal antibody CCR5 receptor antagonist, to be used as a platform drug for a variety of indications.
About CytoDyn
https://www.cytodyn.com/about-cytodyn
About Dr. Pourhassan
https://www.cytodyn.com/our-people/management-team
About Leronlimab
https://www.cytodyn.com/pipeline/covid-19
An excerpt from this page
The acute respiratory distress syndrome (ARDS) of COVID-19 results from the accumulation of neutrophils within the pulmonary circulation and alveolar spaces. Leronlimab (PRO 140) inhibits the migration of Tregs into areas of inflammation, which can inhibit the innate immune response against pathogens and, most importantly, the migration of macrophages and release of pro-inflammatory cytokines in lungs. Leronlimab can potentially mitigate the cytokine storm.
Видео Leronlimab Talk - Dr. Nader Pourhassan CEO of CytoDyn канала Drbeen Medical Lectures
DrBeen team and #koolbeens are super excited to have Dr. Pourhassan with us today. We will discuss Leronlimab with Dr. Pourhassan.
#koolbeens have asked a tons of questions to ask Dr. Pourhassan.
From CytoDyn’s site:
CytoDyn is committed to enhancing the lives of patients through target specific medicine. Our team is focused on developing Leronlimab, a monoclonal antibody CCR5 receptor antagonist, to be used as a platform drug for a variety of indications.
About CytoDyn
https://www.cytodyn.com/about-cytodyn
About Dr. Pourhassan
https://www.cytodyn.com/our-people/management-team
About Leronlimab
https://www.cytodyn.com/pipeline/covid-19
An excerpt from this page
The acute respiratory distress syndrome (ARDS) of COVID-19 results from the accumulation of neutrophils within the pulmonary circulation and alveolar spaces. Leronlimab (PRO 140) inhibits the migration of Tregs into areas of inflammation, which can inhibit the innate immune response against pathogens and, most importantly, the migration of macrophages and release of pro-inflammatory cytokines in lungs. Leronlimab can potentially mitigate the cytokine storm.
Видео Leronlimab Talk - Dr. Nader Pourhassan CEO of CytoDyn канала Drbeen Medical Lectures
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
COVID-19 Insights: LeronlimabOpen DiscussionFamotidine (H2 Receptor Antagonist)Pulmonary Function Tests (PFTs)CytoDyn CEO calls Citron Research report 'false', updates on coronavirus clinical trialsIodine and Its Medical UsesTWIST: Special Guest Tim Grittani Analyzes $CYDY & MoreCOVID-19 Insights: Could Vitamin C Help with COVID-19?Ivermectin Remdesivir LeronlimabCOVID-19 Insights: Quercetin as Zinc Ionophore and COVID-19 Outpatient ManagementCytoDyn hopes to convince FDA & federal gov't to grant approvals with coronavirus patient dataCoQ10 - Coenzyme Q, Electron Transport ChainOxford Vaccine, Moderna, CDC, Test Sensitivity and SpecificityVitamin K Deficiency Leads to Poor COVID-19 OutcomeInhaled Corticosteroids (Budesonide)COVID-19 Insights: Herd Immunity and Second WaveCoronavirus Q&A: The Next COVID-19 PhaseCytoDyn sees impressive results with Leronlimab on very ill COVID-19 patientsAIDS 2020: Virtual DAILY - Episode One ft. Dr Anthony Fauci & Community MembersCOVID-19 Insights: HCQ New Studies, Zinc, Global View